Press Release

Research and Markets (http://www.researchandmarkets.com/research/ef6faa/herpes_simplex_inf) has announced the addition of Global Markets Direct's new report "Herpes Simplex Infections - Pipeline Review, H2 2011" to their offering.

'Herpes Simplex Infections - Pipeline Review, H2 2011', provides an overview of the Herpes Simplex Infections therapeutic pipeline. This report provides information on the therapeutic development for Herpes Simplex Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Herpes Simplex Infections. 'Herpes Simplex Infections - Pipeline Review, H2 2011' is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources

Scope

A snapshot of the global therapeutic scenario for Herpes Simplex Infections. A review of the Herpes Simplex Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. Coverage of products based on various stages of development ranging from discovery till registration stages. A feature on pipeline projects on the basis of monotherapy and combined therapeutics. Coverage of the Herpes Simplex Infections pipeline on the basis of route of administration and molecule type. Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. Key discontinued pipeline projects. Latest news and deals relating to the products.

Reasons to buy

Identify and understand important and diverse types of therapeutics under development for Herpes Simplex Infections. Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. Plan mergers and acquisitions effectively by identifying players with the most promising pipeline. Devise corrective measures for pipeline projects by understanding Herpes Simplex Infections pipeline depth and focus of Herpes Simplex Infections therapeutics. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

For more information visit http://www.researchandmarkets.com/research/ef6faa/herpes_simplex_inf

Business Wire
http://www.businesswire.com/

Last updated on: 01/11/2011 18:00:07

View the original article here